0001209191-23-043447.txt : 20230726 0001209191-23-043447.hdr.sgml : 20230726 20230726171141 ACCESSION NUMBER: 0001209191-23-043447 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230724 FILED AS OF DATE: 20230726 DATE AS OF CHANGE: 20230726 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wallace Courtney CENTRAL INDEX KEY: 0001786410 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 231114435 MAIL ADDRESS: STREET 1: C/O BEAM THERAPEUTICS INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-24 0 0001645666 Kezar Life Sciences, Inc. KZR 0001786410 Wallace Courtney C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 0 Stock Option (Right to Buy) 13.87 2023-07-24 4 D 0 52000 D 2031-12-08 Common Stock 52000 0 D Stock Option (Right to Buy) 2.28 2023-07-24 4 A 0 52000 A 2031-12-08 Common Stock 52000 52000 D Stock Option (Right to Buy) 4.80 2023-07-24 4 D 0 26000 D 2032-06-15 Common Stock 26000 0 D Stock Option (Right to Buy) 2.28 2023-07-24 4 A 0 26000 A 2032-06-15 Common Stock 26000 26000 D One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis following the vesting commencement date of December 9, 2021, subject to the Reporting Person continuing to provide service through each such date. On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. Fully vested and exercisable. /s/ Marc Belsky, Attorney-in-Fact 2023-07-26